Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.21/16388 |
Resumo: | Although the prevalence of severe asthma is not high (5–10% of patients), it is responsible for a large part of the overall disease burden and costs (50–60% of total costs), especially if the condition remains uncontrolled (which occurs in around 40% of cases). Currently, for patients without disease control or presenting frequent exacerbations despite optimal therapy, add-on treatments, traditionally long-acting anticholinergics, oral corticosteroids (OCS), or biologic agents (monoclonal antibodies) are recommended. Nonetheless, the long-term use of oral/systemic corticosteroids (CS) is significantly associated with adverse effects, acute and chronic complications that may decrease health-related quality of life and worsen prognosis, thus requiring additional monitoring and management. Conversely, target therapies (i.e., omalizumab, mepolizumab, reslizumab, benralizumab, and more recently, dupilumab) have been developed grounded on the different phenotypes and endotypes of severe asthma, and are gradually reducing the reliance on OCS (i.e., greater specificity for achieving disease control by reducing the risk of exacerbations and requirements for rescue medication and OCS, with limited adverse events). |
id |
RCAP_3506d343fbb4567b44f815e78d97c68e |
---|---|
oai_identifier_str |
oai:repositorio.ipl.pt:10400.21/16388 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus studyAsthmaSystemic corticosteroidsROSA II ProjectPortuguese ROSA GroupAlthough the prevalence of severe asthma is not high (5–10% of patients), it is responsible for a large part of the overall disease burden and costs (50–60% of total costs), especially if the condition remains uncontrolled (which occurs in around 40% of cases). Currently, for patients without disease control or presenting frequent exacerbations despite optimal therapy, add-on treatments, traditionally long-acting anticholinergics, oral corticosteroids (OCS), or biologic agents (monoclonal antibodies) are recommended. Nonetheless, the long-term use of oral/systemic corticosteroids (CS) is significantly associated with adverse effects, acute and chronic complications that may decrease health-related quality of life and worsen prognosis, thus requiring additional monitoring and management. Conversely, target therapies (i.e., omalizumab, mepolizumab, reslizumab, benralizumab, and more recently, dupilumab) have been developed grounded on the different phenotypes and endotypes of severe asthma, and are gradually reducing the reliance on OCS (i.e., greater specificity for achieving disease control by reducing the risk of exacerbations and requirements for rescue medication and OCS, with limited adverse events).This work was supported by AstraZeneca.ElsevierRCIPLMarques, J.Duarte-Ramos, F.Ferreira, M. B.Lima, R.Lopes, C.Sokolova, A.Tonin, FernandaLoureiro, C. C.2023-08-23T11:03:31Z2023-082023-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/16388engMarques J, Duarte-Ramos F, Ferreira MB, Lima R, Lopes C, Tonin FS, et al. Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study. Pulmonology. 2023;29(6):555-63.10.1016/j.pulmoe.2023.07.003info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-13T02:18:12Zoai:repositorio.ipl.pt:10400.21/16388Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:27:43.076918Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
title |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
spellingShingle |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study Marques, J. Asthma Systemic corticosteroids ROSA II Project Portuguese ROSA Group |
title_short |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
title_full |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
title_fullStr |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
title_full_unstemmed |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
title_sort |
Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study |
author |
Marques, J. |
author_facet |
Marques, J. Duarte-Ramos, F. Ferreira, M. B. Lima, R. Lopes, C. Sokolova, A. Tonin, Fernanda Loureiro, C. C. |
author_role |
author |
author2 |
Duarte-Ramos, F. Ferreira, M. B. Lima, R. Lopes, C. Sokolova, A. Tonin, Fernanda Loureiro, C. C. |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
RCIPL |
dc.contributor.author.fl_str_mv |
Marques, J. Duarte-Ramos, F. Ferreira, M. B. Lima, R. Lopes, C. Sokolova, A. Tonin, Fernanda Loureiro, C. C. |
dc.subject.por.fl_str_mv |
Asthma Systemic corticosteroids ROSA II Project Portuguese ROSA Group |
topic |
Asthma Systemic corticosteroids ROSA II Project Portuguese ROSA Group |
description |
Although the prevalence of severe asthma is not high (5–10% of patients), it is responsible for a large part of the overall disease burden and costs (50–60% of total costs), especially if the condition remains uncontrolled (which occurs in around 40% of cases). Currently, for patients without disease control or presenting frequent exacerbations despite optimal therapy, add-on treatments, traditionally long-acting anticholinergics, oral corticosteroids (OCS), or biologic agents (monoclonal antibodies) are recommended. Nonetheless, the long-term use of oral/systemic corticosteroids (CS) is significantly associated with adverse effects, acute and chronic complications that may decrease health-related quality of life and worsen prognosis, thus requiring additional monitoring and management. Conversely, target therapies (i.e., omalizumab, mepolizumab, reslizumab, benralizumab, and more recently, dupilumab) have been developed grounded on the different phenotypes and endotypes of severe asthma, and are gradually reducing the reliance on OCS (i.e., greater specificity for achieving disease control by reducing the risk of exacerbations and requirements for rescue medication and OCS, with limited adverse events). |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-08-23T11:03:31Z 2023-08 2023-08-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.21/16388 |
url |
http://hdl.handle.net/10400.21/16388 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Marques J, Duarte-Ramos F, Ferreira MB, Lima R, Lopes C, Tonin FS, et al. Optimizing the use of systemic corticosteroids in severe asthma (ROSA II project): a national Delphi consensus study. Pulmonology. 2023;29(6):555-63. 10.1016/j.pulmoe.2023.07.003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133545223946240 |